These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1897042)

  • 1. [Therapy control of perphenazine in paranoid conditions. 1. Organizational aspects].
    Rask PH; Krarup G; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Kjeldsen CS; Klitgaard NA
    Ugeskr Laeger; 1991 Aug; 153(34):2336-9. PubMed ID: 1897042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy control of perphenazine. 2. Clinical aspects].
    Kjeldsen CS; Larsen NE; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Klitgaard NA; Krarup G
    Ugeskr Laeger; 1991 Aug; 153(34):2339-43. PubMed ID: 1897043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of serum monitoring on concentration of perphenazine and zuclopenthixole].
    Thomsen K; Olesen OV; Poulsen JH
    Ugeskr Laeger; 1993 Aug; 155(32):2443-8. PubMed ID: 8356762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perphenazine concentrations in human whole blood. A pilot study during anti-psychotic therapy using different administration forms.
    Hansen CE; Larsen NE
    Psychopharmacologia; 1974 Jun; 37(1):31-6. PubMed ID: 4415024
    [No Abstract]   [Full Text] [Related]  

  • 6. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
    Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F
    Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience with using etaperazine (perphenazine) in the treatment of patients with schizophrenia in a preschool psychiatric department].
    Proselkova ME; Uzhanov NV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(1):120-2. PubMed ID: 1647092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Compulsory procedures in the psychiatric department, Frederiksberg Hospital, before and after introduction of the new psychiatric legislation].
    Schepelern ES; Aggernaes KH; Stender AK; Raben H
    Ugeskr Laeger; 1993 Feb; 155(8):553-7. PubMed ID: 8451790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Paranoid psychosis in acute intermittent porphyria treated with perphenazine].
    Stibolt O; Thunell S
    Ugeskr Laeger; 1998 Nov; 160(45):6529-31. PubMed ID: 9816964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of a consultation center and crisis intervention in addressing psychiatric disorders in the perinatal period].
    Vaiva G; Maron M; Chapoy V; Thomas P; Codaccioni X; Goudemand M
    Encephale; 2002; 28(1):71-6. PubMed ID: 11963346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
    Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
    J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The serum perphenazine level in patients with schizophrenia and the results of treatment].
    Nurowska K; Welbel L; Lipska B; Szukalski B
    Psychiatr Pol; 1987; 21(1):20-5. PubMed ID: 3615673
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice.
    Hansen LB; Larsen NE
    Psychopharmacology (Berl); 1985; 87(1):16-9. PubMed ID: 3933033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Compulsory procedures at the Psychiatric Department, Frederiksberg Hospital, before and after introduction of the new psychiatric legislation. 3. Compulsory medication].
    Schepelern ES; Aggernaes KH; Stender AK; Raben H
    Ugeskr Laeger; 1994 Sep; 156(38):5524-7. PubMed ID: 7941088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks.
    Larsen NE; Hansen LB
    Ther Drug Monit; 1989 Nov; 11(6):642-6. PubMed ID: 2595744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical psychopathological research on late-onset schizophrenia--mainly patients with schizophrenia from a hospital psychiatric ward].
    Yasuda M; Kato S
    Seishin Shinkeigaku Zasshi; 2009; 111(3):250-71. PubMed ID: 19425390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Perphenazine enanthate. Results of a 1-year open multicenter study].
    Baruch P; Brion S; Broussolle P; Gayral LF; Ropert R; Volmat R; Porot M
    Encephale; 1989; 15(5):449-55. PubMed ID: 2686965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.